Staggering prices slow insurers' coverage of gene therapy

Two approved cancer therapies, with price tags of hundreds of thousands of dollars, have roiled the insurance approval process, leading to delays and, in some cases, denials of coverage.

By Michelle Andrews, Kaiser Health News | July 18, 2018 at 09:49 AM

chemotherapy gene therapy insurance approval Related: Why you should know what 'pharmacogenetics' is CAR T-cell therapy approved for people up to age 25 Kymriah Yescarta as long as five years more than $1 million cost as well as the drugs' effectiveness KHN's coverage of prescription drug development, costs and pricing is supported in part by the Laura and John Arnold Foundation. Kaiser Health News (KHN) is a national health policy news service. It is an editorially independent program of the Henry J. Kaiser Family Foundation which is not affiliated with Kaiser Permanente.

NOT FOR REPRINT

1 House committee proposes plan to cut back on federal employee pensions

2 Understanding Subrogation: Best Practices for Benefits Advisors and TPAs

3 9 in 10 Americans have put off health checkups, life-saving screenings

4 Pharmacist group tells Elon Musk's team to probe pharmacy benefit managers

5 Sutter Health to pay $228.5M to settle antitrust lawsuit

Insurance
BenefitsPRO Broker Expo 2025
May 06, 2025 - Boston

The premier educational and networking event for employee benefits brokers and agents.
More Information
Workers' Compensation Risk Management Award for Excellence Nominations
May 05, 2025 - Nomination Deadline

The 2025 Workers Comp Risk Management Award for Excellence honors outstanding loss control, safety and return-to-work programs.
More Information
Consulting
Consulting Top Consultants 2025
June 26, 2025 - New York

Consulting Magazine identifies consultants that have the biggest impact on their clients, firms and the profession.
More Information